Friday, 16 October 2026European Markets

CRCAM NORM.SEINE And TOTENS SPAREBANK Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam norm.seine (ccn.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam norm.seine (ccn.pa) €77.01 5.19% 3.01%
totens sparebank (totg.ol) kr198.00 4.59% 10.47%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam norm.seine (ccn.pa)

5.19% forward dividend yield and 3.01% return on equity

caisse régionale de crédit agricole mutuel de normandie-seine société cooperativ offers various banking products and services to individuals, professionals, farmers, associations, and companies in france. it provides savings accounts; credit products; property, personal, life, and pension insurance products; factoring; brokerage; investment banking; asset management; real estate promotion services; specialized funding products; and various loans. the company was incorporated in 2000 and is headquartered in bois guillaume, france. caisse régionale de crédit agricole mutuel de normandie-seine société coopérativ is a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam norm.seine has a trailing twelve months eps of €13.46.

pe ratio

crcam norm.seine has a trailing twelve months price to earnings ratio of 5.72. meaning, the purchaser of the share is investing €5.72 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.01%.

revenue growth

year-on-year quarterly revenue growth declined by 5.7%, now sitting on 345.52m for the twelve trailing months.

dividend yield

according to morningstar, inc., the next dividend payment is on may 15, 2023, the estimated forward annual dividend rate is 4.1 and the estimated forward annual dividend yield is 5.19%.

moving average

crcam norm.seine's worth is higher than its 50-day moving average of €73.98 and above its 200-day moving average of €72.20.

more news about crcam norm.seine.

2. totens sparebank (totg.ol)

4.59% forward dividend yield and 10.47% return on equity

totens sparebank provides various banking and financial products and services in norway. the company offers savings and pension products; business and construction loans; leasing; overdrafts and bank guarantees; liability, business, data attack, property damage, craftsman, health, homeowners, collective, personnel, travel, occupational injury, agriculture, and vehicle insurance; and business and credit cards. it also provides online and mobile banking services; payment solutions; asset management; and real estate services. totens sparebank was founded in 1854 and is headquartered in lena, norway.

earnings per share

as for profitability, totens sparebank has a trailing twelve months eps of kr20.53.

pe ratio

totens sparebank has a trailing twelve months price to earnings ratio of 9.64. meaning, the purchaser of the share is investing kr9.64 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.47%.

moving average

totens sparebank's value is under its 50-day moving average of kr218.04 and below its 200-day moving average of kr204.65.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, totens sparebank's stock is considered to be oversold (<=20).

growth estimates quarters

the company's growth estimates for the present quarter and the next is 51.7% and 14.9%, respectively.

volume

today's last reported volume for totens sparebank is 6 which is 98.83% below its average volume of 513.

more news about totens sparebank.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com